This episode, titled Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies, features expert nephrologists discussing the following critical questions: What ...
In the final episode, Near-Term Priorities for Transforming Clinical Practice in IgA Nephropathy, the panelist explored the following critical question: What do you hope to see in the next 1–2 years ...
Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted accelerated approval for Fabhalta to treat proteinuria in patients with primary IgA ...
AUSTIN, Texas -- Once-daily sparsentan (Filspari) was better at reducing proteinuria than standard treatment in IgA nephropathy, according to a prespecified interim analysis of the PROTECT trial. By ...
Andrew S. Bomback, MD, MPH, recalls a patient from over a decade ago, who traveled to New York for a second opinion on his IgA nephropathy diagnosis. The patient had researched his condition and ...
Immunoglobulin A (IgA) nephropathy is an autoimmune condition that causes inflammation and damage in your kidneys, which may lead to kidney failure over time. IgA nephropathy develops when IgA builds ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics ...
The final analysis showed treatment with sparsentan reduced the rate of decline in kidney function vs irbesartan. The Food and Drug Administration (FDA) has granted full approval to Filspari ® ...
HOUSTON -- A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients with IgA nephropathy, interim findings from the phase III ORIGIN 3 trial ...
Novartis (NYSE:NVS) reported interim results from a Phase 3 study of its drug candidate astrasentan in the treatment of IgA nephropathy, a rare type of kidney disease. The Swiss drugmaker said the ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Well, I think I wouldn't be exaggerating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results